Ruti Aga: Six Years, and a Prescription That Never Reached a Clinic

Investigators were handed a prescription. It carried a clinic's name, a doctor's name, and one drug: methylprednisolone. When the Athletics Integrity Unit (AIU) wrote to the clinic, the answer came back that no such entity existed on its register. The person who had written the slip held no medical registration — he was a member of the athlete's family. And the explanation he offered, that the paper came from an old prescription pad left at a former workplace, was flatly disowned by the clinic itself.

Three verifications. Three separate places where the paper fell apart.

The athlete at the centre of this is not a marginal name. Ruti Aga, 32, Ethiopian marathoner, a career in the 2:18–2:20 class. Winner of the 2026 Tokyo Marathon, and three-time runner-up at World Marathon Majors. In March she won a half marathon in China, and the in-competition sample from that race returned positive for methylprednisolone. She had been provisionally suspended from 10 September, and that same date now anchors a six-year ban.

Start with the thing most coverage got wrong. Methylprednisolone was widely described as a "prohibited steroid" and said to be classed as performance-enhancing by WADA. That classification is incorrect. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List, not an anabolic steroid (S1). And the decisive condition on S9 is this: it is prohibited in-competition only, and only by injection, oral or rectal route. A therapeutic knee injection given out of competition is entirely legitimate.

That distinction is not pedantry. It is the hinge on which the whole case turns. For a marathoner with an inflamed knee, intra-articular methylprednisolone is among the most routine procedures in sports medicine. If the treatment in March was real, the only live questions were the date of the injection and the date of the race. A documented medical record, a TUE application, or simply a correct washout interval — any one of those three would have stopped this from becoming a case at all.

Instead of documentation, the response was fabrication.

The sanction arithmetic is simple and worth reading slowly. Two years for the presence violation, four for tampering. The two-year figure is the standard outcome for a Specified Substance where intent is not established. The four-year figure is the Code's standard tampering sanction. The sum tells us the panel rejected the no-significant-fault mitigation — it did not accept that the athlete had simply handed over the wrong paperwork in good faith.

Here is the part that sounds backwards: had Aga done nothing at all, the likeliest outcome was a two-year ban. Whether the knee treatment was genuine or invented was not something a panel could settle. What it could settle was whether the prescription put before it was real. It was not. That single finding converted two years into six — and six years at 32 means a return at 38. In the depth of Ethiopian women's marathoning, a 38-year-old with a doping record on file is not a selection question anyone entertains.

I have always built the grid before watching the result. In August 2026 the Athens long jump final landed on my desk because no senior writer wanted it; I logged all six jumps, the wind readings, the board distances, into a spreadsheet, and the desk chief called it overkill. Two years later he asked for the template. The lesson from that habit is narrow and durable: when the paper and the result disagree, trust neither.

In this case both are lying, in opposite directions.

What makes the story interesting is not the drug. Methylprednisolone has no established endurance benefit. It reduces inflammation, masks pain, and its effect on performance is unproven. A six-year ban has landed on a substance whose ergogenic value nobody has demonstrated. The two-year presence sanction rests on the same substance, and only because residues were present on race day. The entire weight of the punishment sits on the paperwork, not the pharmacology.

That breaks a common assumption. This is not the case of a sprinter caught on steroids. It is the case of an athlete who had no credentialed team physician. The "doctor" was family, the clinic on the letterhead did not exist, and the defence collapsed on first contact. An injured marathoner whose income depends on appearance fees and Major-circuit invitations reaches for the cheapest available tool to hide pain — and there is no institutional medical structure around her pointing to the correct one. The forged slip is downstream of that absence, not the cause of it.

Which raises the question the AIU statement leaves untouched. Nowhere in the six-year outcome is there a finding on where the agent, the manager, or any camp official stood while that document was manufactured. The family member is named. Nobody else is. A 32-year-old forging paperwork alone is possible; in this industry it is the least likely explanation available. Until that question is asked, the sanction stays with the individual and the structure that made it necessary survives intact.

A caution is also owed. Not every unreconciled document is corruption. Two decades of audit work teaches that most of the time it is understaffing, paper chaos, or a clerk who never filed. That reading does not survive here, because three independent verifications failed and one of them was a direct denial. But what the evidence proves is narrow: a false document was created and submitted. It does not prove the knee treatment was invented, nor that no other option existed before March. That gap is exactly what sets the outer limit of the sanction.

What to watch now. The AIU statement does not say whether the March half marathon result and its prize money will be annulled — standard procedure disqualifies the competition at which the sample was collected, and ranking points accrue afterwards are forfeit. Nor is it settled that the 2026 Tokyo title survives; the violation is tied to a March race, so earlier results are not automatically void absent a finding of prior use.

The larger question sits with the circuit. China's label-race tier, where large appearance-fee budgets meet deep East African elite fields, has become the AIU's most productive testing ground. The money and the sample collection now occupy the same races. If more cases follow in the coming months — a substance violation compounded by a paperwork violation — it will confirm that the enforcement frontier has moved from detection to document verification. Ruti Aga is the first name on that frontier, not the last.